Associate Consulting Professor in the Department of Psychiatry and Behavioral Sciences, Division of Child and Family Mental Health and Developmental Neuroscience at Duke University School of Medicine
Dr. Joe Horrigan is a pediatric neuropsychiatrist. He sees patients for differential diagnosis, assessment and medical management within the clinics affiliated with the Duke Center for Autism and Brain Development. Dr. Horrigan also teaches trainees within Duke School of Medicine and Duke University as related to the diagnosis and treatment of individuals with developmental neuropsychiatric disorders. In addition, Dr. Horrigan assists with the development of protocols and research programs within the Duke Center for Autism and Brain Development with special emphasis on translational treatment development, interactions with the FDA and associations with industry.
Dr. Horrigan obtained his medical degree from the University of Rochester School of Medicine and Dentistry, and he completed his residency training in general psychiatry, fellowship training in child and adolescent psychiatry, and an additional fellowship in pediatric neuropsychiatry, all at the University of North Carolina at Chapel Hill. Subsequently, Dr. Horrigan served on the faculty at the University of North Carolina at Chapel Hill where he was a clinician and an investigator in studies in the Developmental Neuropharmacology Clinic. Several of these studies contributed to the approval of new medicines for children with neuropsychiatric disorders. Subsequent to this, Dr. Horrigan worked at GlaxoSmithKline for almost 10 years, specializing in study design and the execution of clinical development plans in psychiatry and neurology. He initiated and co-led the Medicines for Children Advisory Network at GlaxoSmithKline, providing scientific and clinical advice across all therapeutic areas, and he also co-led the Pediatric Working Group of the International Federation of Pharmaceutical Manufacturers and Associations.
Subsequently, Dr. Horrigan joined Autism Speaks, the world’s largest science and advocacy organization for individuals affected by autism spectrum disorders. Dr. Horrigan served as the inaugural Head of Medical Research for Autism Speaks before transitioning to a role as the Vice President of Clinical Development and Medical Affairs at Neuren Pharmaceuticals, based in New Zealand, where he composed and directed clinical programs in Rett syndrome, Fragile X syndrome, concussion and traumatic brain injury. In this capacity, he worked closely with patient advocacy organizations, worldwide clinical experts, and the United States Army. Most recently, Dr. Horrigan has been serving as Chief Medical Officer for AMO Pharma Limited in the United Kingdom, which is focusing on rare genetic disorders for which there are few if any effective treatments, such as myotonic dystrophy. During all of this time, Dr. Horrigan has continued to provide patient care with a specialty interest in the psychopharmacology needs across the lifespan of individuals with neurodevelopmental disorders.
1. Horrigan JP, Barnhill LJ (1995), Guanfacine for Treatment of Attention- Deficit Hyperactivity Disorder in Boys. Journal of Child and Adolescent Psychopharmacology, 5(3): 215-223.
2. Horrigan JP, Barnhill LJ (1997), Risperidone and Explosive, Aggressive Autism. Journal of Autism and Developmental Disorders, 27(3): 313-323.
3. Horrigan JP, Barnhill LJ (1999), Guanfacine and Secondary Mania in Children. Journal of Affective Disorders, 54(3): 309-314.
4. Horrigan JP, Barnhill LJ (2000), Low-dose Amphetamine Salts and Adult Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 61(6): 414-417.
5. Horrigan JP (2001), Present and Future Pharmacotherapies for Adult Attention-Deficit/Hyperactivity Disorder. Expert Opinion on Pharmacotherapy, 2(4): 573-586.
6. Barnhill J, Horrigan JP (2002), Tourette’s Syndrome and Autism: A Search for Common Ground. Mental Health Aspects of Developmental Disabilities, 5(1): 7-15.
7. Wilens TE, Haight BR, Horrigan JP et al. (2005), Bupropion XL in Adults with ADHD: A Randomized, Placebo-Controlled Study. Biological Psychiatry, 57(7):793-801.
8. Krulewicz S, Carpenter DJ, Fong R, Horrigan JP et al. (2006), Analysis of Electrocardiographic Data Following Use of Paroxetine in Pediatric Depression and Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45(4):422-430.
9. Clayton AH, Croft H, Horrigan JP et al. (2006), Bupropion Extended Release Compared with Escitalopram: Effects on Sexual Functioning and Antidepressant Efficacy in Two Randomized, Double-Blind, Placebo-Controlled Studies. Journal of Clinical Psychiatry, 67(5):736-746.
10. Moore HK, Hughes CW, Mundt JC, Rush AJ, Macleod L, Emslie GJ, Jain S, Geralts DS, Bernstein IH, Horrigan JP, Trivedi MH, Greist JH (2007), A Pilot Study of an Electronic, Adolescent Version of the Quick Inventory of Depressive Symptomatology, Journal of Clinical Psychiatry, 68(9):1436-1440.
11. Bielski RJ, Cunningham L, Horrigan JP et al. (2008), Gepirone Extended-Release in the Treatment of Adult Outpatients with Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study. Journal of Clinical Psychiatry, 69(4):571-577.
12. Santen G, Horrigan J, Danhof M, Della-Pasqua O (2009), From Trial and Error to Trial Simulation II: An Appraisal of Current Beliefs in Clinical Research Practice in Depression. Clinical Pharmacology and Therapeutics, 86(3): 255-262.
13. Kraus JE, Horrigan JP, Carpenter DJ, Fong R, Barrett PS, Davies JT (2010), Clinical Features of Patients with Treatment-Emergent Suicidal Behavior Following Initiation of Paroxetine Therapy. Journal of Affective Disorders, 120(1): 40-47.
14. Miller DH, Weber T, Grove R, Wardell C, Horrigan JP, et al. (2012), Firategrast for Relapsing Remitting Multiple Sclerosis: a Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Neurology 11(2):131-139.
15. Grove RA, Shackelford S, Sopper S, Pirruccello S, Horrigan JP et al. (2013), Leukocyte Counts in Cerebrospinal Fluid and Blood Following Firategrast Treatment in Subjects with Relapsing Forms of Multiple Sclerosis. European Journal of Neurology 20(7):1032-1042.
16. Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls A, Boardley RL, Berges AC, Nathan PJ, Horrigan JP (2014), A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK2395132 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease. Current Alzheimer Research 11(1):47-58.
17. Lecavalier L, Wood JJ, Halladay AK, Jones NE, Aman MG, Bodfish JW, Cook EH, Handen BL, King BH, Pearson DA, Hallett V, Sullivan KA, Grondhuis S, Bishop SL, Horrigan JP, Dawson G, Scahill L (2014), Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders 44(5):1128-1143.
18. Scahill L, Aman MG, Bishop SL, Lecavalier L, Bodfish JW, Grondhuis S, Halladay AK, Jones N, Horrigan JP , Cook EH, Handen BL, King BH, Pearson DA, McCracken JT, Stamper KS, Dawson G (2015), Measuring Repetitive Behaviors as a Treatment Endpoint in Youth with Autism Spectrum Disorder. Autism 19(1):38-52.
19. Jarskog LF, Lowy MT, Grove RA, Keefe RSE, Horrigan JP, et al. (2015), A Phase 2 Study of a Histamine H3 Receptor Antagonist GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Antipsychotic Therapy. Schizophrenia Research 164(1-3):136-142.
20. Anagnostou E, Jones N, Huerta M, Halladay AK, Wang P, Scahill L, Horrigan JP, Kasari C, Lord C, Choi D, Sullivan K, Dawson G (2015), Measuring Social Communication Behaviors as a Treatment Endpoint in Individuals with Autism Spectrum Disorder. Autism 19(5):622-36.
21. Neul JL, Glaze DG, Percy AK, Feyma T, Beisang A, Dinh T, Suter B, Anagnostou E, Snape M, Horrigan J, Jones NE (2015), Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale. Journal of Child Neurology 30(13): 1743-1748.
22. Findling RL, Chang K, Robb A, Foster VJ, Horrigan J et al. (2015), Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study. Journal of the American Academy of Child and Adolescent Psychiatry 54(12):1020-1031.